Insider Buying: Organogenesis Holdings Inc (NASDAQ:ORGO) Director Buys $5,156,791.00 in Stock

Organogenesis Holdings Inc (NASDAQ:ORGO) Director Avista Capital Managing Member bought 860,900 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average cost of $5.99 per share, for a total transaction of $5,156,791.00.

Avista Capital Managing Member also recently made the following trade(s):

  • On Tuesday, September 10th, Avista Capital Managing Member bought 537,000 shares of Organogenesis stock. The stock was acquired at an average cost of $5.18 per share, for a total transaction of $2,781,660.00.

ORGO stock opened at $5.73 on Thursday. The company has a debt-to-equity ratio of 3.78, a quick ratio of 1.14 and a current ratio of 1.51. The firm’s 50 day moving average price is $4.69. Organogenesis Holdings Inc has a one year low of $3.56 and a one year high of $310.90.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.11) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. The firm had revenue of $64.95 million for the quarter, compared to analysts’ expectations of $61.00 million. Analysts forecast that Organogenesis Holdings Inc will post -0.5 earnings per share for the current year.

ORGO has been the topic of several analyst reports. Credit Suisse Group initiated coverage on shares of Organogenesis in a research report on Monday, August 26th. They set an “outperform” rating on the stock. BTIG Research set a $12.00 price target on shares of Organogenesis and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Zacks Investment Research lowered shares of Organogenesis from a “hold” rating to a “sell” rating in a research report on Tuesday, September 10th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $10.80.

Several hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC purchased a new stake in shares of Organogenesis during the 2nd quarter valued at approximately $200,000. Vanguard Group Inc. raised its position in shares of Organogenesis by 33.3% during the 2nd quarter. Vanguard Group Inc. now owns 323,292 shares of the company’s stock valued at $2,457,000 after buying an additional 80,852 shares during the period. BlackRock Inc. raised its position in shares of Organogenesis by 716.3% during the 2nd quarter. BlackRock Inc. now owns 554,838 shares of the company’s stock valued at $4,217,000 after buying an additional 486,870 shares during the period. Northern Trust Corp raised its position in shares of Organogenesis by 134.3% during the 2nd quarter. Northern Trust Corp now owns 41,066 shares of the company’s stock valued at $312,000 after buying an additional 23,540 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Organogenesis during the 2nd quarter valued at approximately $210,000. 1.68% of the stock is currently owned by hedge funds and other institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

Featured Article: Bond

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit